Zydus Lifesciences Share Price Rises on Exclusive Licensing Deal With Synthon | Stock Market Today

Market Performance

The stock market today opened on a positive note for Zydus Lifesciences. The share price gained momentum in early trade, reacting to the company’s latest announcement.

• At 09:19 am, Zydus Lifesciences was trading at ₹1,020.00, up by ₹8.00 or 0.79% on the BSE.
• The move followed a fresh update about its subsidiary entering into a strategic licensing and supply agreement.

Main News

Zydus Lifesciences Global FZE, a wholly owned arm of the company, has signed an exclusive licensing and supply agreement with Synthon BV (Netherlands).

The partnership is focused on Ozanimod Capsules for the US market, a treatment aimed at relapsing forms of multiple sclerosis (MS).

Under this agreement:

• Synthon will handle the regulatory approvals for Ozanimod in the US.
• It will also be responsible for manufacturing and supply once approvals are in place.
• Zydus will manage the commercialization of the product across the US.

This positions Zydus Lifesciences strategically in a high-potential therapeutic segment.

Company Details

The deal comes at a crucial time as Synthon already has a pending Abbreviated New Drug Application (ANDA) with the US FDA.

• Synthon has received tentative approval within 30 months of filing.
• This milestone makes the product eligible for a shared 180-day exclusivity period upon launch in the US market.

The agreement strengthens Zydus’ foothold in the global pharmaceutical landscape, particularly in the specialty therapy area of neurology.

Adding to this momentum, Zydus has been active on multiple fronts recently:

• VaxiFlu™ Launch: Earlier this month, the company introduced its trivalent influenza (flu) vaccine in India, aligned with WHO global recommendations.
• Clinical Trial Progress: In August, its subsidiary Zydus Therapeutics reported positive topline results from the pivotal EPICS-III Phase 2(b)/3 clinical trial.

Financial Snapshot

Zydus Lifesciences has also reported steady growth in its financial performance for Q1 FY26:

• Revenue from operations: ₹6,573.7 crore (up 5.9% YoY)
• Net profit: ₹1,466.8 crore (up 3.3% YoY)

These numbers reflect consistent operational strength, alongside its expanding product pipeline and international collaborations.

Summary

The rise in Zydus Lifesciences share price today mirrors investor optimism around its exclusive deal with Synthon BV. With Ozanimod Capsules moving closer to approval in the US, and a steady line of new product launches and clinical trial progress, Zydus is showing resilience both in the domestic and international markets.

For investors tracking the stock market today, Zydus Lifesciences remains in focus as it combines strategic partnerships, regulatory progress, and financial stability—all key triggers that often influence market sentiment.